Ablation stent for treating atrial fibrillation

Information

  • Patent Grant
  • 7209783
  • Patent Number
    7,209,783
  • Date Filed
    Tuesday, April 16, 2002
    22 years ago
  • Date Issued
    Tuesday, April 24, 2007
    17 years ago
Abstract
An apparatus and method for treating atrial fibrillation with ablation therapy in which a stent is deployed within a pulmonary vein and tissue surrounding the stent is ablated with radiofrequency energy to stop discharges from ectopic foci in the vein from reaching the left atrium. The deployed stent can then be left in place to prevent stenosis of the vein as well as allowing repeat ablation procedures as needed.
Description
FIELD OF THE INVENTION

This invention pertains to methods for treating atrial tachyarrhythmias such as atrial fibrillation. In particular, the invention relates to an apparatus and method for treating atrial fibrillation by ablation therapy.


BACKGROUND

Fibrillation refers to a condition in which muscle fibrils enter a state of extremely rapid, small-scale contractions that do not coordinate to effect contraction of the muscle as a whole. When this occurs in the left ventricle, the heart chamber responsible for pumping blood into the arterial vasculature, it is serious and rapidly fatal. When it occurs in the musculature of the atria, it is less immediately serious and not necessarily fatal. It is still important to treat atrial fibrillation, however, for several reasons. First, atrial fibrillation is associated with a loss of atrio-ventricular synchrony which can be hemodynamically compromising and cause such symptoms as dyspnea, fatigue, vertigo, and angina. Atrial fibrillation can also predispose to strokes resulting from emboli forming in the left atrium. Although drug therapy, in-hospital cardioversion, and implantable cardioverter/defibrillators are acceptable treatment modalities for atrial fibrillation, a curative approach such as ablation therapy offers a number of advantages to certain patients, including convenience and greater efficacy.


Electrical ablation therapy treats cardiac arrhythmias by destroying myocardial tissue involved in the initiation or maintenance of the tachyarrhythmia. Ablation is most often accomplished by delivering radiofrequency electrical energy through a catheter electrode that has been placed next to the tissue to be destroyed. One way that the technique has been employed in order to treat atrial fibrillation is to identify ectopic sites or reentrant pathways electrophysiologically and then eliminate them by radiofrequency catheter ablation. Recent evidence has shown that the great majority of paroxysms of atrial fibrillation are initiated by trains of rapid discharges originating from the pulmonary veins. Accordingly, catheter techniques have been developed for ablating these sites with radiofrequency energy applied from within the pulmonary veins, but electrophysiological mapping of such sites is difficult. Alternatively, another technique involves the production of a circumferential ablation lesion within a pulmonary vein in order to block the conduction pathway from the vein to the left atrium. An effective circumferential lesion must be completely continuous, however, and this means that the ablation device must be precisely located within the vein or ostium, which may be difficult to accomplish. Furthermore, a common complication of this procedure is pulmonary venous stenosis resulting from scarring within the pulmonary vein which has variable clinical consequences.


SUMMARY OF THE INVENTION

An objective of the present invention is to provide an improved apparatus and method for pulmonary vein ablation in order to treat atrial fibrillation. In accordance with the invention, a stent catheter having a stent mounted thereon is introduced into the left atrium of a patient. The stent is deployed by expansion of the stent within a pulmonary vein or ostium of the vein. The stent expansion may be performed with a balloon at the distal end of the stent catheter or by a self-expanding stent. Tissue surrounding the deployed stent is then ablated to stop discharges from ectopic foci in the vein from reaching the left atrium. After the ablation, the stent is left in place in order to prevent stenosis of the vein.


In order to produce the ablation, radiofrequency energy is transmitted into the surrounding tissue by means of a catheter making contact with the stent which then causes heating of the surrounding tissue. The stent may have electrodes for transmitting current to the surrounding tissue or the stent itself may be used as an electrode. The ablation lesions in the tissue surrounding the stent may be selectively produced so as to destroy one or more ectopic foci, or a circumferential lesion may be produced that interrupts a conduction pathway between the vein and the left atrium.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A depicts a stent catheter with a stent mounted at one end.



FIG. 1B shows a balloon catheter with an electrode for delivering energy to a deployed stent.



FIG. 2A shows one embodiment of a stent with annular electrodes.



FIG. 2B shows an embodiment of a stent with a plurality of patch electrodes.



FIGS. 3A–3D depict the steps in one method for forming an electrode on the surface of a stent.



FIG. 4 shows another embodiment of a stent with structures for preventing dislodgement after the stent is deployed.



FIG. 5 shows a stent with temperature sensing elements.





DETAILED DESCRIPTION OF THE INVENTION

As noted above, it has been found that the ectopic foci responsible for most episodes of atrial fibrillation are found in the pulmonary veins. The pulmonary veins empty into the left atrium, and a myocardial muscle sleeve extends over the proximal segment of the veins. The myocytes in these pulmonary vein sleeves, unlike ordinary atrial myocytes, exhibit spontaneous activity and can thus constitute ectopic sites responsible for initiating and maintaining atrial fibrillation. In order to block the discharges from these myocytes with ablation therapy, either the myocytes themselves are destroyed or an ablation lesion is made that destroys excitable tissue in the pathway leading from the myocytes to the left atrium.


Shown in FIG. 1A is a depiction of a stent catheter 100 having a balloon 120 at its distal end. Fitted around the balloon 120 is a vascular stent 110, which is a tubular structure made of metal or synthetic material capable of being deployed in a pulmonary vein similar to the way arterial stents are deployed in peripheral or coronary arteries. Pressurized fluid applied to the proximal end of the catheter passes through a lumen within the catheter and inflates the balloon 120. Inflating the balloon 120 expands the stent 110 against the walls of a blood vessel and thereby deploys the stent in a fixed position within the vessel. In an alternate embodiment, the stent may be designed to be self-expanding such as by mechanical means or by being constructed of a shape-memory alloy such as nitinol.


The stent catheter 100 with the stent 110 fixed thereon may be positioned in a pulmonary vein using an over the wire catheterization technique in which a radio-opaque catheter, or guidewire over which the catheter slides, is passed into a patient's vascular system under fluoroscopic guidance. Vascular access is obtained by puncturing a vessel and seating a hemostatic valve within the puncture wound. The stent catheter is then passed into the patient's vascular system through the valve. In one approach, the catheter is introduced into a peripheral vein and then advanced through the vena cava and into the right atrium. From there, the catheter is positioned against the fossa ovalis in the atrial septum, and a needle or trochar is advanced distally through a lumen of the stent catheter and out the distal end to puncture the fossa ovalis. The catheter is then passed through the atrial septum to reach the left atrium and gain access to the pulmonary veins. In another approach, the catheter is advanced into the left atrium from the arterial system by accessing a peripheral artery and advancing the catheter into the aorta, around the aortic arch, into the left ventricle, and then into the left atrium through the mitral valve. With either approach, after reaching the left atrium, the distal end of the stent catheter 100 is advanced into a selected pulmonary vein to position the stent 110 within either the vein or the ostium of the vein where the conduction block is to be formed. Alternatively, the stent deployment could be done during open-heart surgery or a transthoracic surgical procedure. In that case, rather than a catheter, a plunger-type instrument could be used to deploy the stent and apply energy thereto to produce the ablation lesion. Saline infusion for cooling could also be applied through the plunger type instrument.


The stent 110 is deployed by expanding the stent within the vein by, for example, inflating balloon 120 over which the stent 110 is fitted. Tissue surrounding the deployed stent is then ablated so as to stop discharges from ectopic foci in the vein from reaching the left atrium. The ablation lesions in the tissue surrounding the stent may be selectively produced so as to destroy one or more ectopic foci, or a circumferential lesion may be produced that interrupts a conduction pathway between the vein and the left atrium. After the ablation lesion has been produced, the stent is left in place in order to prevent stenosis of the vein as a result of fibrosis and scarring.


In order to produce the ablation lesion, radiofrequency energy is applied to the stent which causes thermal heating of the surrounding tissue. The result is either a circumferential conduction block around the vein which isolates myocytes in the vein distal to the lesion or localized destruction of ectopic foci. Such energy can be applied from the stent catheter or from a separately introduced ablation catheter which contacts the stent and transmits electrical energy thereto. FIG. 1B shows an embodiment of a stent catheter 100 in which an electrode 121 is mounted on the balloon 120. The electrode 121 is connected internal to the balloon to a conductor 101 that extends through the lumen of the catheter so that electrical energy can be applied to the electrode. With either a catheter such as that shown in FIG. 1B or a separate ablation catheter, radiofrequency energy is transmitted from the catheter to the stent which either acts as an electrode or has separate ablation electrodes mounted thereon as described below.


The stent itself may be used as an electrode or may have separate electrodes for transmitting current to the surrounding tissue. In the former case, the stent may be made of any electrically conductive material such as platinum, silver, gold, stainless steel, nitinol, or titanium. FIG. 2A shows an exemplary stent design in which the stent 110 has one or more annular electrodes 111 mounted thereon which effect a cirumferential burn when radiofrequency energy is applied to the electrodes. Preferably, the annular electrodes are constructed so as to produce a circumferentially continuous lesion when electrical energy is applied. FIG. 2B shows another embodiment in which the stent 110 has one or more patch electrodes 112 placed at selected locations on the surface of the stent. Such patch electrodes are electrically conductive areas on the stent surface which may be of any desired shape.


Separate electrodes on the stent may be of the same material or a separate material which may be formed on the stent by, for example, sputter coating or vapor deposition. FIGS. 3A through 3D show one method for making an annular electrode on a stent. FIG. 3A shows a stent 110 made of electrically conductive material. An annular mask 200 is then applied to the stent 110 at the location where an electrode is desired as shown in FIG. 3B. Next, a non-conductive dielectric coating 201 is applied to the entire stent as shown in FIG. 3C. FIG. 3D shows the resulting stent with an electrically conductive annular electrode 113 after the mask is removed.


In order to reduce the risk of thrombus formation, a coating of heparin or other anti-coagulant can be applied to the stent before deployment. In addition, mechanical anchoring devices may be incorporated into the stent in order to prevent dislodgement after the stent is deployed. FIG. 4 illustrates one example of such a stent in which a plurality of hooks 114 are mounted on a stent 110. The hooks 114 are oriented so as to allow the stent to be pushed retrogradely through a pulmonary vein without resistance but prevent it from being pushed out in the other direction by blood flow. Other anchoring devices mounted on the stent, such as tines, spikes, or barbs, may similarly be employed to fix the stent in place after deployment.


During the ablation procedure, it may be useful to monitor the temperature of the tissue as it is heated by the ablation electrodes. Accordingly, FIG. 5 illustrates a modified ablation stent 110 with ablation electrodes 112 and which also has one or more temperature sensors 115 mounted thereon. The temperature sensors (e.g., thermocouples or resistive temperature devices) are connected via a conductor running through the catheter to monitoring equipment at the proximal end of the catheter in order to provide feedback to an operator as current is supplied to the ablation electrodes.


As described above, using a deployed vascular stent as a vehicle for delivering ablation energy to a selected location greatly facilitates the ablation procedure and produces more consistent results. In the event a first ablation procedure is not satisfactory, however, having the stent already deployed also allows any repeat ablation procedures to be more easily performed.


Although the invention has been described in conjunction with the foregoing specific embodiment, many alternatives, variations, and modifications will be apparent to those of ordinary skill in the art. Such alternatives, variations, and modifications are intended to fall within the scope of the following appended claims.

Claims
  • 1. A method for treating atrial fibrillation, comprising: introducing a stent into the left atrium of a patient, wherein the stent is introduced by a stent catheter having a stent mounted at its distal end;deploying the stent into a pulmonary vein by inflating a balloon at the distal end of the stent catheter to expand the stent within a pulmonary vein,applying radiofrequency energy to the deployed stent in order to ablate surrounding tissue and stop discharges from ectopic foci in the vein from reaching the left atrium,leaving the stent in place in order to prevent stenosis of the vein; and,transmitting the radiofrequency energy to the stent by an electrode mounted on the surface of the balloon.
  • 2. The method of claim 1 further comprising transmitting the radiofrequency energy into the surrounding tissue by means of a catheter making contact with the stent.
  • 3. The method of claim 1 wherein the stent acts as an electrode when radiofrequency energy is applied thereto so that tissue surrounding the stent is ablated and forms a circumferential lesion that interrupts a conduction pathway between the vein and the left atrium.
  • 4. The method of claim 1 wherein radiofrequency energy is applied to electrodes mounted on the stent to thereby ablate tissue in contact with the electrodes.
  • 5. The method of claim 1 wherein the stent has one or more anchoring devices mounted thereon that serve to prevent dislodgment after the stent is deployed in a pulmonary vein.
  • 6. The method of claim 1 further comprising performing one or more additional ablation procedures after the stent is deployed by applying radiofrequency energy to the deployed stent if a first ablation procedure did not produce satisfactory results.
  • 7. The method of claim 1 further comprising advancing the stent catheter transvenously into the left atrium through the atrial septum.
  • 8. An apparatus for treating atrial fibrillation, comprising: a stent catheter having a stent mounted thereon for deployment in a pulmonary vein, the catheter including a balloon at its distal end for expanding the stent within a pulmonary vein and,an electrode located on the surface of the balloon for making contact with the deployed stent and for transmitting radiofrequency energy thereto in order to ablate surrounding tissue and stop discharges from ectopic foci in the vein from reaching the left atrium.
  • 9. The apparatus of claim 8 further comprising one or more electrodes mounted on the stent for contacting surrounding tissue and producing an ablation lesion when energy is applied thereto.
  • 10. The apparatus of claim 8 wherein the stent electrode is an annular electrode.
  • 11. The apparatus of claim 8 wherein the stent electrode is a patch electrode.
  • 12. The apparatus of claim 8 wherein the stent is constructed of an electrically conductive material and further wherein a dielectric coating is applied to the outer surface of the stent leaving a selected area exposed to serve as an electrode.
  • 13. The apparatus of claim 8 further comprising one or more anchoring devices mounted on the surface of the stent to prevent dislodgement after the stent is deployed.
  • 14. An apparatus for treating atrial fibrillation, comprising: a stent catheter means having a stent mounted thereon for deployment in a pulmonary vein, the catheter including a balloon at its distal end for expanding the stent within a pulmonary vein, wherein the stent is coated with an anti-coagulant to prevent thrombus formation;one or more anchoring devices mounted on the surface of the stent to prevent dislodgment after the stent is deployed; and,an electrode located on the surface of the balloon for transmitting radiofrequency energy to the deployed stent in order to ablate surrounding tissue and stop discharges from ectopic foci in the vein from reaching the left atrium.
CROSS-REFERENCE TO RELATED APPLICATION(S)

This application claims the benefit of U.S. Provisional Application No. 60/298,738, filed on Jun. 15, 2001, under 35 U.S.C. 119(e).

US Referenced Citations (103)
Number Name Date Kind
3692027 Ellinwood, Jr. Sep 1972 A
4003379 Ellinwood, Jr. Jan 1977 A
4146029 Ellinwood, Jr. Mar 1979 A
4281664 Duggan Aug 1981 A
4299220 Dorman Nov 1981 A
4544371 Dormandy, Jr. et al. Oct 1985 A
4556063 Thompson et al. Dec 1985 A
4686987 Salo et al. Aug 1987 A
4871351 Feingold Oct 1989 A
4897987 Spaila Feb 1990 A
4944299 Silvian Jul 1990 A
4987897 Funke Jan 1991 A
5040533 Fearnot Aug 1991 A
5041107 Heil, Jr. Aug 1991 A
5042497 Shapland Aug 1991 A
5058581 Silvian Oct 1991 A
5087243 Avitall Feb 1992 A
5127404 Wyborny et al. Jul 1992 A
5190035 Salo et al. Mar 1993 A
5220917 Cammilli et al. Jun 1993 A
5269301 Cohen Dec 1993 A
5284136 Hauck et al. Feb 1994 A
5305745 Zacouto Apr 1994 A
5342408 deCoriolis et al. Aug 1994 A
5353800 Pohndorf et al. Oct 1994 A
5368028 Palti Nov 1994 A
5404877 Nolan et al. Apr 1995 A
5416695 Stutman et al. May 1995 A
5456692 Smith, Jr. et al. Oct 1995 A
5460605 Tuttle et al. Oct 1995 A
5496360 Hoffmann et al. Mar 1996 A
5499971 Shapland et al. Mar 1996 A
5551953 Lattin et al. Sep 1996 A
5556421 Prutchi et al. Sep 1996 A
5562713 Silvian Oct 1996 A
5579876 Adrian et al. Dec 1996 A
5586556 Spivey et al. Dec 1996 A
5607418 Arzbaecher Mar 1997 A
5607463 Schwartz et al. Mar 1997 A
5634899 Shapland et al. Jun 1997 A
5662689 Elsberry et al. Sep 1997 A
5690682 Buscemi et al. Nov 1997 A
5693075 Plicchi et al. Dec 1997 A
5720770 Nappholz et al. Feb 1998 A
5730125 Prutchi et al. Mar 1998 A
5800498 Obino et al. Sep 1998 A
5814089 Stokes et al. Sep 1998 A
5817131 Elsberry et al. Oct 1998 A
5833603 Kovacs et al. Nov 1998 A
5836935 Ashton et al. Nov 1998 A
5893881 Elsberry et al. Apr 1999 A
5899928 Sholder et al. May 1999 A
5925066 Kroll et al. Jul 1999 A
5949659 Lesche Sep 1999 A
5954761 Macheck et al. Sep 1999 A
5967986 Cimochowski et al. Oct 1999 A
5980563 Tu et al. Nov 1999 A
5980566 Alt et al. Nov 1999 A
5991668 Leinders et al. Nov 1999 A
6016447 Juran et al. Jan 2000 A
6016448 Busacker et al. Jan 2000 A
6024740 Lesh et al. Feb 2000 A
6115636 Ryan Sep 2000 A
6140740 Porat et al. Oct 2000 A
6141588 Cox et al. Oct 2000 A
6154675 Juran et al. Nov 2000 A
6168801 Heil, Jr. et al. Jan 2001 B1
6179789 Tu et al. Jan 2001 B1
6198394 Jacobsen et al. Mar 2001 B1
6200265 Walsh et al. Mar 2001 B1
6206914 Soykan et al. Mar 2001 B1
6213942 Flach et al. Apr 2001 B1
6231516 Keilman et al. May 2001 B1
6237398 Porat et al. May 2001 B1
6251109 Hassett et al. Jun 2001 B1
6254573 Haim et al. Jul 2001 B1
6277078 Porat et al. Aug 2001 B1
6298272 Peterfeso et al. Oct 2001 B1
6309370 Haim et al. Oct 2001 B1
6317615 KenKnight et al. Nov 2001 B1
6358202 Arent Mar 2002 B1
6361522 Scheiner et al. Mar 2002 B1
6361780 Ley et al. Mar 2002 B1
6424847 Mastrototaro et al. Jul 2002 B1
6442413 Silver Aug 2002 B1
6443949 Altman Sep 2002 B2
6453195 Thompson Sep 2002 B1
6459917 Gowda et al. Oct 2002 B1
6501983 Natarajan et al. Dec 2002 B1
6511477 Altman et al. Jan 2003 B2
6514249 Maguire et al. Feb 2003 B1
6518245 Anderson et al. Feb 2003 B1
6519488 KenKnight et al. Feb 2003 B2
6542781 Koblish et al. Apr 2003 B1
6632223 Keane Oct 2003 B1
6645145 Dreschel et al. Nov 2003 B1
6662045 Zheng et al. Dec 2003 B2
6716242 Altman Apr 2004 B1
20010000802 Soykan et al. May 2001 A1
20020026228 Schauerte Feb 2002 A1
20030004403 Drinan et al. Jan 2003 A1
20030069606 Girouard et al. Apr 2003 A1
20030158584 Cates et al. Aug 2003 A1
Foreign Referenced Citations (3)
Number Date Country
0054138 Jun 1982 EP
1050265 Nov 2000 EP
WO 9733513 Sep 1997 WO
Related Publications (1)
Number Date Country
20030018362 A1 Jan 2003 US
Provisional Applications (1)
Number Date Country
60298738 Jun 2001 US